Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00329628 · ClinicalTrials.gov registry record · Phase 3
Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,541
- Enrollment target
NCT00329628: Completed Phase 3 study, sponsored by Bayer.
NCT00329628 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 4,541 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (488% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00329628, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,541 participants
- Enrollment target
Study Summary
The purpose of this study is to assess if 10 mg BAY 59-7939, taken once daily as a tablet, is safe and prevent blood clot which may form after total hip replacement operation.
Interventions
- DRUG Enoxaparin
- DRUG Rivaroxaban (BAY59-7939)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,541 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-03 |
| Phase | Phase 3 |
What the finished NCT00329628 record still lists
NCT00329628 is an interventional study that assigns participants to a tested intervention. Its 4,541 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (488% higher).
The record links to 0 conditions, and to 2 interventions - of which Enoxaparin is the first listed.
NCT00329628 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00329628 about?
NCT00329628 is a clinical study titled "Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin". The purpose of this study is to assess if 10 mg BAY 59-7939, taken once daily as a tablet, is safe and prevent blood clot which may form after total hip replacement operation.
What is the current status of trial NCT00329628?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,541 participants. The study started on 2006-02. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00329628?
The interventions under investigation include: Enoxaparin (DRUG), Rivaroxaban (BAY59-7939) (DRUG).
Who is sponsoring clinical trial NCT00329628?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00329628's enrollment target sits among peer trials
4,541 54th of 2000 higher than 1,947 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06702878 · 4,514 participants · Phase 3
Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections
- NCT06533111 · 4,500 participants · NA
Improving Surgical Patient Outcomes Through Implementation of a SemiStructured Intraoperative Anesthesia Handoff Tool
- NCT06588452 · 4,500 participants
Manual Versus AI-Assisted Clinical Trial Screening Using Large-Language Models
- NCT07165028 · 4,500 participants · Phase 3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia